NDAORALTABLET
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
27
Data completeness
4/8 — Partial
VOYDEYA (danicopan) by AstraZeneca is complement factor d inhibitors [moa]. First approved in 2024.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOYDEYA (danicopan) is an oral complement Factor D inhibitor approved by the FDA on March 29, 2024. It works by blocking the alternative pathway of the complement system, reducing excessive complement activation. The drug is indicated for patients with complement-mediated diseases, though specific indications require clinical context.
Growth11.9 years to LOE
Early-stage product in growth phase with no current competitive pressure; brand team has runway to establish market position and build commercial infrastructure.
Mechanism of Action
Complement Factor D Inhibitors
Pharmacologic Class:
Complement Factor D Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (27)
Danicopan PMS in Korea
Started Apr 2026
27 enrolled
Paroxysmal Nocturnal Hemoglobinuria
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
Started Jan 2026
50 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNH
Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
Started Aug 2025
50 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNH
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
Started Aug 2025
6 enrolled
Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Started Oct 2022
80 enrolled
Paroxysmal Nocturnal Hemoglobinuria
Worked on VOYDEYA at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.